» Articles » PMID: 8287600

Expression of High-affinity IL-4 Receptors on Human Melanoma, Ovarian and Breast Carcinoma Cells

Overview
Date 1994 Jan 1
PMID 8287600
Citations 40
Authors
Affiliations
Soon will be listed here.
Abstract

It has previously been shown that murine sarcoma cells express high-affinity IL-4 receptors (IL-4R) which are internalized after binding to the ligand (Puri et al., Cancer Res 1991; 51:3011-7). We have also reported that human renal cell carcinoma cells express high-affinity IL-4R, and IL-4 inhibits tumour growth in vitro (Obiri et al., J Clin Invest 1993; 91:88). In this study we investigated the expression and function of IL-4R on other human solid tumours. Human melanoma, ovarian carcinoma and breast carcinoma cell lines were assessed for the cell surface expression of IL-4R by radio-ligand receptor binding and for IL-4R gene expression by Northern blot analysis. Primary cultures of mesothelioma and neurofibrosarcoma cells were similarly investigated. Human melanoma, ovarian carcinoma and breast carcinoma cell lines expressed IL-4R on their cell surface with a dissociation constant (Kd) of 140-549 pM. These tumour lines expressed a single 4 kb species of mRNA for IL-4R. Similarly, primary cultures of mesothelioma and neurofibrosarcoma cells were positive for the IL-4R mRNA by Northern blot analysis. Fresh, non-cultured mesothelioma and neurofibrosarcoma tumour sections were also positive for the presence of IL-4R as determined by immunohistochemistry of frozen sections using anti-IL-4R antibody. In order to study possible functions of IL-4R, we evaluated the effects of IL-4 on cell growth and its effect on MHC antigen expression in the presence or absence of interferon-gamma (IFN-gamma). In tissue culture, IL-4 reduced the growth of tumour cell lines and primary cell cultures studied. IL-4 had very little effect on MHC class I antigen expression on ovarian, breast and melanoma cell lines; however, MHC class II (HLA-DR) expression was enhanced on melanoma and breast carcinoma cells. IL-4 also enhanced the IFN-gamma-induced class II expression on melanoma and breast carcinoma cells. Taken together, our observations indicate that IL-4R are expressed on a variety of human solid tumours and these receptors may be functional. IL-4 alone and in combination with IFN-gamma may play a role in host immune response against cancers.

Citing Articles

Peptides as multifunctional players in cancer therapy.

Vadevoo S, Gurung S, Lee H, Gunassekaran G, Lee S, Yoon J Exp Mol Med. 2023; 55(6):1099-1109.

PMID: 37258584 PMC: 10318096. DOI: 10.1038/s12276-023-01016-x.


Application of bioengineered elastin-like polypeptide-based system for targeted gene delivery in tumor cells.

Yi A, Sim D, Lee S, Sarangthem V, Park R Biomater Biosyst. 2023; 6:100050.

PMID: 36824163 PMC: 9934475. DOI: 10.1016/j.bbiosy.2022.100050.


Breast cancers co-opt normal mechanisms of tolerance to promote immune evasion and metastasis.

Crump L, Kines K, Richer J, Lyons T Am J Physiol Cell Physiol. 2022; 323(5):C1475-C1495.

PMID: 36189970 PMC: 9662806. DOI: 10.1152/ajpcell.00189.2022.


Interleukin-4 Receptor Targeting Peptide Decorated Extracellular Vesicles as a Platform for In Vivo Drug Delivery to Thyroid Cancer.

Gangadaran P, Gunassekaran G, Rajendran R, Oh J, Vadevoo S, Lee H Biomedicines. 2022; 10(8).

PMID: 36009525 PMC: 9406005. DOI: 10.3390/biomedicines10081978.


Engineered Cytokine Signaling to Improve CAR T Cell Effector Function.

Bell M, Gottschalk S Front Immunol. 2021; 12:684642.

PMID: 34177932 PMC: 8220823. DOI: 10.3389/fimmu.2021.684642.


References
1.
Bosco M, Giovarelli M, Forni M, Modesti A, Scarpa S, Masuelli L . Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory. J Immunol. 1990; 145(9):3136-43. View

2.
Lee J, Swisher S, Minehart E, McBride W, Economou J . Interleukin-4 downregulates interleukin-6 production in human peripheral blood mononuclear cells. J Leukoc Biol. 1990; 47(5):475-9. DOI: 10.1002/jlb.47.5.475. View

3.
Lichtenstein A, Berenson J, Gera J, Waldburger K, Martinez-Maza O, Berek J . Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes. Cancer Res. 1990; 50(22):7364-70. View

4.
Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T . Identification of a T cell-derived b cell growth factor distinct from interleukin 2. J Exp Med. 1982; 155(3):914-23. PMC: 2186613. DOI: 10.1084/jem.155.3.914. View

5.
Green L, Reade J, Ware C . Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J Immunol Methods. 1984; 70(2):257-68. DOI: 10.1016/0022-1759(84)90190-x. View